metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Tratamiento de la toxicidad renal en el paciente positivo al virus de la inmunod...
Información de la revista
Vol. 26. Núm. S8.
Tenofovir DF, una experiencia de más de 5 años
Páginas 55-61 (junio 2008)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 26. Núm. S8.
Tenofovir DF, una experiencia de más de 5 años
Páginas 55-61 (junio 2008)
Acceso a texto completo
Tratamiento de la toxicidad renal en el paciente positivo al virus de la inmunodeficiencia humana. Qué medir, cómo medirlo y con qué frecuencia
Management of renal toxicity in HIV-positive patients. What to measure, how to measure it and frequency
Visitas
1754
Guillermina Barril Cuadradoa,
Autor para correspondencia
gbarril43@gmail.com

Correspondencia: Servicio de Nefrología. Hospital Universitario de la Princesa. Diego de León, 62. 28006 Madrid. España.
, Ignacio de los Santos Gilb
a Servicio de Nefrología. Hospital Universitario de la Princesa. Madrid. España
b Servicio de Medicina Interna-Infecciosas. Hospital Universitario de la Princesa. Madrid. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

La enfermedad renal crónica en pacientes con infección por el virus de la inmunodeficiencia humana se está poniendo de manifiesto como una de las comorbilidades más frecuentes, por lo que, actualmente, su estudio es un campo abierto. Las manifestaciones que pueden aparecer son muy variadas, por lo que se debe tener alto índice de vigilancia y ya desde la primera visita del paciente realizar los estudios adecuados para descartarla y evitar el empeoramiento con las medidas diagnósticas o terapéuticas que posteriormente se deban aplicar. Uno de los problemas más habituales es la nefrotoxicidad de algunos fármacos y cada vez son más frecuentes los casos descritos asociados a tenofovir. Sin embargo, la experiencia clínica con este fármaco es muy extensa y su toxicidad renal es poco habitual, tanto en ensayos clínicos como en la práctica clínica. Lo importante es conocer bien qué es lo que puede ocurrir, los factores colaboradores y controlar de manera adecuada a los pacientes.

Palabras clave:
Tenofovir
Hipofosfatemia
Síndrome de Fanconi
Proteinuria
VIH

Chronic kidney disease in patients with HIV is being recognized as one of the most frequent comorbidities of this disease and consequently much research is currently being performed in this area. The possible manifestations are highly varied and consequently a high index of suspicion is required. Appropriate investigations should be performed from the moment patients first seek care to rule out renal disease and to prevent worsening, with the diagnostic or therapeutic measures that may subsequently be required. One of the most common problems is nephrotoxicity caused by some drugs and cases associated with tenofovir are becoming more frequently described. However, there is wide clinical experience with this drug and renal toxicity associated with its use is uncommon both in clinical trials and in clinical practice. Familiarity with what may happen, the associated factors and appropriate patient management are essential.

Key words:
Tenofovir
Hypophosphatemia
Fanconi syndrome
Proteinuria
HIV
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.K. Gupta, B.W. Manlin, C.S. Jonson, M.D. Dollins, J.M. Topf, M.P. Dube.
Prevalence of proteinuira and the development of chronic kidney disease in HIV-infected patients.
Clin Nephrol, 61 (2004), pp. 1-6
[2.]
F.J. Palella Jr, R.K. Baker, A.C. Moorman.
Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV Outpatient Study.
J Acquir Immune Defic Syndr, 43 (2006), pp. 27-34
[3.]
H.M. Crane, S.E. Van Rompaey, M.M. Kitahata.
Antiretroviral medications associated with elevated blood pressure among patients recieving highly active antiretroviral therapy.
AIDS, 2 (2006), pp. 1019-1026
[4.]
C. Gazzaruso, R. Bruno, A. Garzaniti, S. Giordanetti, P. Fratino, P. Sacchi, et al.
Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome.
J Hypertension, 21 (2003), pp. 1377-1382
[5.]
H. Knobel, C. Jerico, M. Montero, M.L. Sorli, M. Velat, A. Guelar, et al.
Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Frammingham, SCORE, and PROCAM).
AIDS patient Care STDS, 21 (2007), pp. 452-457
[6.]
C.M. Wyatt, R.R. Arons, P.E. Klotman, M.E. Klotman.
Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality.
[7.]
J.M. Miró, J. Torre-Cisnero, A. Moreno, M. Tuset, C. Quereda, M. Laguno, et al.
GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005).
Enferm Infecc Microbiol Clin, 23 (2005), pp. 353-362
[8.]
A.S. Levey, J. Coresh, E. Balk, A.T. Kausz, A. Levin, M.W. Steffes, et al.
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification and stratification.
Ann Intern Med, 139 (2003), pp. 137-147
[9.]
S.K. Fernando, F.O. Finkelstein, B.A. Moore, S. Weissman.
Prevalence of Chronic Kidney disease in a urban HIV infected population.
Am J Med Sci, 335 (2008), pp. 89-94
[10.]
J. Winston, D.H. Shepp.
Estimating renal function in patients on tenofovir disoproxil fumarate: suggestion for safer use.
[11.]
A.S. Levey, J.P. Bosch, J.B. Lewis.
A more accurate method for estimate glomerular filtration rate from serum creatinine: a new predictor equation.
Ann Intern Med, 130 (1999), pp. 461-470
[12.]
S.K. Gupta, J.A. Eustace, J.A. Winston.
Guidelines for the management of chronic kidney disease in HIV infected patients. Recommendations of the HIV Medicine Association of infectious diseases Society of America.
Clin Infect Dis, 40 (2005), pp. 1559-1585
[13.]
K/DOQI clinical practice guidlines for chronic Kidney disease: evaluation, clasification and stratification.
Am J Kidney Dis, 39 (2002), pp. 51-266
[14.]
D.W. Crockoft, M.H. Gault.
Prediction of creatinine clearance from serum creatinine.
Nephron, 16 (1976), pp. 31-41
[15.]
E. Selvin, J. Manzi, L.A. Stevens, F. Van Lente, D.A. Lacher, A.S. Levey, et al.
Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004.
Am J Kidney Dis, 50 (2007), pp. 918-926
[16.]
H. Gatanaga, N. Tachikawa, Y. Kikichi, K. Teruya, I. Genka, M. Honda, et al.
Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate.
AIDS Res Hum Retroviruses, 22 (2006), pp. 744-748
[17.]
N.M. Brim, S. Cu-Uvia, S.L. Hu, J.W. O’Bell.
Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome.
AIDS Read, 17 (2007), pp. 326-327
[18.]
S.L. Day, H.A. Leake Date, A. Bannister, M. Hankins, M. Fisher.
Serum hypophosphatemia in Tenofovir Disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice.
J Acquir Immune Defic Syndr, 38 (2005), pp. 301-304
[19.]
C.A. Fux, A. Christen, S. Zgraggen, M.G. Mohaupt, H. Furrer.
Effect of tenofovir on renal glomerular and tubular function.
AIDS, 11 (2007), pp. 1483-1485
[20.]
I. Cassetti, R. Madruga, J.M. Suleiman, A. Etzel, L. Zhong, A.K. Cheng, et al.
Seguridad y eficacia de tenofovir DF en combinación con lamivudina y efavirenz durante 6 años en pacientes naïve infectados por el VIH-1.
HIV Clinical Trials, 8 (2007), pp. 164-172
[21.]
H. Izzedine, J.S. Hulot, D. Vittecoq, J.E. Gallant, S. Staszewsky, V. Launay-Vacher, et al.
Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral- naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.
Nephrol Dial Transplant, 20 (2005), pp. 743-746
[22.]
R. Jones, J. Stebbing, M. Nelson, G. Moyle, M. Bower, S. Mandalia, et al.
Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study.
J Acquir Immune Defic Syndr, 37 (2004), pp. 1489-1495
[23.]
J.R. Arribas, A.L. Pozniak, J.E. Gallant, E. DeJesús, B. Gazzard, R.E. Campo, et al.
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
J Acquir Immune Defic Syndr, 47 (2008), pp. 74-78
[24.]
J.E. Gallant, S. Staszewsky, A.L. Pozniak, E. DeJesús, J.M. Suleiman, M.D. Miller, et al.
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
JAMA, 192 (2004), pp. 191-201
[25.]
A. Viganò, G.V. Zuccoti, L. Martelli, V. Giacomet, L. Cafarelli, S. Borgonovo, et al.
Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study.
Clin Drug Invest, 27 (2007), pp. 573-581
[26.]
M.R. Nelson, C. Katlama, J.S. Montaner, D.A. Cooper, B. Gazzard, B. Clotet, et al.
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS, 21 (2007), pp. 1273-1281
[27.]
J.E. Gallant, M.A. Parish, J.C. Keruly, R.Dl. Moore.
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.
Clin Infect Dis, 40 (2005), pp. 1194-1198
[28.]
S.K. Gupta.
Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.
AIDS Patient care STDS, 22 (2008), pp. 99-103
[29.]
A.E. Zimmermann, T. Pizzoferrato, J. Bedford, A. Morris, R. Hoffman, G. Braden.
Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions.
Clin Infect Dis, 42 (2006), pp. 283-290
[30.]
J. Roling, H. Schmid, M. Fischereder, R. Draenert, F.D. Goebel.
HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.
Clin Infect Dis, 42 (2006), pp. 1488-1495
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.eimc.2020.09.012
No mostrar más